Literature DB >> 15867500

Reintroduction of the 2G12 epitope in an HIV-1 clade C gp120.

Hongying Chen1, Xiaodong Xu, Alexandra Bishop, Ian M Jones.   

Abstract

Many clade C isolates of HIV-1 do not react with monoclonal antibody (MAb) 2G12, a broad-ranging human neutralizing MAb that recognizes high mannose carbohydrate groups attached to glycoprotein gp120. We reintroduced a partial and complete 2G12 epitope into a clade C background, HIV-1(CN54), and examined the antibody reactivity of the resulting recombinant molecules. Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15867500     DOI： 10.1097/01.aids.0000168980.74713.9e

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  11 in total

1.  Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.

Authors:  Qiang Yang; Cishan Li; Yadong Wei; Wei Huang; Lai-Xi Wang
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

2.  Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Authors:  Kabamba B Alexandre; Elin S Gray; Bronwen E Lambson; Penny L Moore; Isaac A Choge; Koleka Mlisana; Salim S Abdool Karim; James McMahon; Barry O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2010-04-13       Impact factor: 3.616

3.  Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.

Authors:  Shariq Mujib; Jun Liu; A K M Nur-Ur Rahman; Jordan A Schwartz; Phil Bonner; Feng Yun Yue; Mario A Ostrowski
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

4.  HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.

Authors:  Maria J Duenas-Decamp; Paul R Clapham
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

Authors:  Kabamba B Alexandre; Penny L Moore; Molati Nonyane; Elin S Gray; Nthabeleng Ranchobe; Ereck Chakauya; James B McMahon; Barry R O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2013-08-15       Impact factor: 3.616

6.  N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.

Authors:  Elin S Gray; Penny L Moore; Ralph A Pantophlet; Lynn Morris
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

7.  Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.

Authors:  Leopold Kong; Neil C Sheppard; Guillaume B E Stewart-Jones; Cynthia L Robson; Hongying Chen; Xiaodong Xu; George Krashias; Camille Bonomelli; Christopher N Scanlan; Peter D Kwong; Simon A Jeffs; Ian M Jones; Quentin J Sattentau
Journal:  J Mol Biol       Date:  2010-08-25       Impact factor: 5.469

8.  Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Authors:  Elin Solomonovna Gray; Tammy Meyers; Glenda Gray; David Charles Montefiori; Lynn Morris
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

9.  Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.

Authors:  Heidi E Drummer; Melissa K Hill; Anne L Maerz; Stephanie Wood; Paul A Ramsland; Johnson Mak; Pantelis Poumbourios
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  Immunogenicity of the outer domain of a HIV-1 clade C gp120.

Authors:  Hongying Chen; Xiaodong Xu; Ian M Jones
Journal:  Retrovirology       Date:  2007-05-17       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.